A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation: Expert Review of Vaccines: Vol 14, No 3
A randomized, phase 2 study of ASP0113, a DNA‐based vaccine, for the prevention of CMV in CMV‐seronegative kidney transplant recipients receiving a kidney from a CMV‐seropositive donor - Vincenti - 2018 -
IJMS | Free Full-Text | Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy | HTML
Another Vical vax flop, this time with Astellas-partnered CMV vaccine | Fierce Biotech
Vaccines | Free Full-Text | Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan | HTML
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. - Abstract - Europe PMC
A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection | npj Vaccines
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
Vaccines | Free Full-Text | Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan | HTML
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
PDF) A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients
Vaccines | Free Full-Text | Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice | HTML
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
Vical's Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipients | Fierce Pharma
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - ScienceDirect
Kidney Transplant | Dr. Piotr Witkowski | UChicago
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
Astellas' ASP0113 Trial Failure Gives Merck's Prevymis Further CMV Boost :: Scrip
Astellas Pharma US | Results for Cytomegalovirus Vaccine ASP0113 Trial
Astellas, Vical's Lead CMV Vaccine Flunks Key Phase III Study | BioSpace
Pursuing Victory: Moderna Begins Dosing in Phase III CMV Trial
